F. De Vincenzo
19 Papers
135 Citations
F. De Vincenzo is an academic researcher. The author has contributed to research in topics: Pemetrexed & Vinorelbine. The author has an hindex of 9, co-authored 19 publications.
Chat about Author
Papers
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
Giovanni Luca Ceresoli,B. Castagneto,Paolo Andrea Zucali,Adolfo Favaretto,Manlio Mencoboni,Francesco Grossi,Diego Cortinovis,G. Del Conte,Anna Ceribelli,Alessandra Bearz,S. Salamina,F. De Vincenzo,Federico Cappuzzo,Maurizio Marangolo,Valter Torri,Armando Santoro +15 more
TL;DR: The PC regimen is effective and well tolerated in selected elderly patients with MPM, and there was no significant difference in outcome or toxicity between age groups.
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Paolo Andrea Zucali,Matteo Perrino,Elena Lorenzi,Giovanni Luca Ceresoli,F. De Vincenzo,Matteo Simonelli,Letizia Gianoncelli,R. De Sanctis,Laura Giordano,Armando Santoro +9 more
TL;DR: Vinorelbine was moderately active in pemetrexed-pretreated MPM patients, with an acceptable toxicity profile, particularly in patients with ECOG-PS0 and FL-PFS ≥ 6 months, and significantly associated to OS in multivariate analysis.
56
Reproducibility of the WHO classification of thymomas: Practical implications
Paolo Andrea Zucali,L. Di Tommaso,Iacopo Petrini,Serena Battista,Hye Seung Lee,Maria J. Merino,Elena Lorenzi,Emanuele Voulaz,F. De Vincenzo,Matteo Simonelli,Massimo Roncalli,Laura Giordano,Marco Alloisio,Armando Santoro,G. Giaccone +14 more
TL;DR: The agreement on WHO classification of thymomas was only moderate and this impacted on patients management and the histotype showed a statistically significant impact on PFS and DRS in the classification provided by only two pathologists.
41
Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours
Paolo Andrea Zucali,Matteo Simonelli,F. De Vincenzo,Elena Lorenzi,Matteo Perrino,Monica Bertossi,R Finotto,S. Naimo,Luca Balzarini,C. Bonifacio,I Timofeeva,G. Rossoni,G. Mazzola,Antonio Lambiase,Claudio Bordignon,Claudio Bordignon,Armando Santoro +16 more
TL;DR: NGR–hTNF can be safely escalated at doses higher than MTD and induces low receptors shedding and early antivascular effects and lower sTNF-R2 levels and greater Ktrans decreases after first cycle were associated with improved survival.
Impact of soluble tumor necrosis factor-receptors (stnf-rs) shedding on outcome in patients treated with ngr-htnf
Paolo Andrea Zucali,Matteo Simonelli,F. De Vincenzo,Elena Lorenzi,Armando Santoro,Antonio Lambiase,Claudio Bordignon +6 more
TL;DR: Lambiase et al. as discussed by the authors found that early treatment-induced changes in sTNF-R2 shedding may identify patients who have a greater likelihood of benefit from NGR-hTNF.
10